- Home
- ZIM vs AUPH Comparison
ZIM vs AUPH Comparison
Compare ZIM & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIM
- AUPH
- Stock Information
- Founded
- ZIM 1945
- AUPH 1993
- Country
- ZIM Israel
- AUPH Canada
- Employees
- ZIM N/A
- AUPH N/A
- Industry
- ZIM Marine Transportation
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- ZIM Consumer Discretionary
- AUPH Health Care
- Exchange
- ZIM Nasdaq
- AUPH Nasdaq
- Market Cap
- ZIM 1.8B
- AUPH 1.6B
- IPO Year
- ZIM 2021
- AUPH 1999
- Fundamental
- Price
- ZIM $16.05
- AUPH $15.33
- Analyst Decision
- ZIM Sell
- AUPH Strong Buy
- Analyst Count
- ZIM 4
- AUPH 3
- Target Price
- ZIM $13.27
- AUPH $17.67
- AVG Volume (30 Days)
- ZIM 4.1M
- AUPH 1.9M
- Earning Date
- ZIM 11-20-2025
- AUPH 11-04-2025
- Dividend Yield
- ZIM 44.57%
- AUPH N/A
- EPS Growth
- ZIM N/A
- AUPH N/A
- EPS
- ZIM 16.63
- AUPH 0.55
- Revenue
- ZIM $8,575,100,000.00
- AUPH $265,808,000.00
- Revenue This Year
- ZIM N/A
- AUPH $17.33
- Revenue Next Year
- ZIM N/A
- AUPH $14.31
- P/E Ratio
- ZIM $0.96
- AUPH $27.90
- Revenue Growth
- ZIM 43.57
- AUPH 20.62
- 52 Week Low
- ZIM $11.04
- AUPH $6.55
- 52 Week High
- ZIM $30.15
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- ZIM 65.12
- AUPH 71.77
- Support Level
- ZIM $14.82
- AUPH $13.34
- Resistance Level
- ZIM $16.48
- AUPH $15.98
- Average True Range (ATR)
- ZIM 0.62
- AUPH 0.82
- MACD
- ZIM 0.14
- AUPH 0.23
- Stochastic Oscillator
- ZIM 81.38
- AUPH 79.95
About ZIM ZIM Integrated Shipping Services Ltd.
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.